Biotech Values

[jbog]

ENTA's EPS will ramp up during the calendar year as the Mavyret royalty rate climbs from the 10% lowest tier in calendar 1Q20 (ENTA's FY2Q20) to higher royalty tiers in subsequent quarters.

The data I worked on I want to say was at the 3rd qtr last year showed me that with any amount of decline in Abby's sales would result in Enanta not reaching the top level.

I'll try to find my notes.